ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Routine Sampling Of Breast Duct Cells For Detection Of Cancer Precursors Possible With Ductal Lavage System

July 28, 2000

Senate Subcommittee Okays $1 billion For NCI In FY 1980, Agrees To Block Obey Reprogramming

June 15, 1979

First Mobil NMR Scanner Goes Into Operation At Temple

June 22, 1984

Authorizes $2.7 Billion For NCI, 7% Prevention

May 28, 1993

Gallo To Give Scripps Symposium’s Schwartz Lecture

August 9, 1985

NIES Issue RFA For Studies On Alternative Types Of Cancer Bioassay

October 31, 1980